EU approves Incresync for Type 2 Diabetes
The European Commission has granted Marketing Authorization (MA) for Incresync (alogliptin with pioglitazone), from Takeda, for the treatment of Type 2 Diabetes patients who are uncontrolled on existing therapies. Takeda received approval for alogliptin (Nesina) in 2010 and in fixed-dose combination with pioglitazone (Liovel) in 2011 in Japan. Common adverse events reported with patients treated with alogliptin co-administered with pioglitazone include upper respiratory tract infection, sinusitis, nausea, dyspepsia, abdominal pain, pruritus, peripheral edema and increased weight.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins